Last updated: March 27, 2026
What is ORTHO-NOVUM 1/35-28?
ORTHO-NOVUM 1/35-28 is a combination oral contraceptive formulation containing norgestimate (1 mg) and ethinyl estradiol (35 µg). It is administered in a 28-day pack with 21 active pills and 7 placebo pills. The drug primarily targets the reproductive health segment, focusing on contraception.
Market Size and Segment Analysis
Global Birth Control Market
The global contraceptives market reached USD 22.4 billion in 2021 and is projected to grow at CAGR 4.7% through 2028. Combined oral contraceptives (COCs) accounted for approximately 36% of this market in 2021, valued around USD 8 billion.
| Year |
Market Size (USD billion) |
COC Share (%) |
COC Market Value (USD billion) |
| 2021 |
22.4 |
36% |
8.1 |
| 2028 (proj.) |
~34.2 |
36% |
~12.3 |
Key Geographies
- North America: Largest market, driven by high contraceptive use, USD 4.5 billion in 2021.
- Europe: USD 2.3 billion, steady growth due to increasing acceptance and availability.
- Asia-Pacific: Fastest growth, expected CAGR 6.2%, driven by population growth and rising awareness.
Competitive Landscape
Major players include Pfizer, Bayer, Teva, and Allergan. Brand dominance varies per region, with some local generics competing aggressively.
Market Drivers
- Increasing awareness of reproductive health.
- Rising preference for oral contraceptives over invasive methods.
- Regulatory approvals expanding authorized indications.
- Growing acceptance in Asian markets with large young populations.
Market Challenges
- Concerns around side effects and safety.
- Regulatory restrictions in certain countries.
- Competition from long-acting reversible contraceptives (LARCs), like IUDs and implants.
- Patent expirations and the proliferation of generic versions reducing prices.
Product Lifecycle and Patent Status
Orthoe-NOVUM 1/35-28, introduced in the 1990s, faces patent expiry risks and generic competition. The original patent expired in numerous markets by 2010, with extended exclusivity in some jurisdictions due to formulation patents or regulatory data protections.
Patent and Exclusivity Timeline
| Country |
Patent Expiry |
Market Exclusivity Status |
| US |
2010+ |
Generic versions available |
| EU |
2011+ |
Generics introduced post-expiry |
| Japan |
2012 |
Generic competition present |
Revenue Projections and Financial Trajectory
Revenue Estimates (2021-2028)
- Baseline sales in 2021: USD 450 million, primarily in North America and Europe.
- Growth assumptions: 2-3% CAGR from 2021 to 2028 factoring in market saturation and generic competition.
- Potential impact of increased generic penetration: flattening or slight decline post-patent expiry.
| Year |
Estimated Sales (USD millions) |
Key Influencers |
| 2021 |
450 |
Brand dominance, leading markets |
| 2024 |
480 |
Growing competition, price erosion |
| 2028 |
420 |
Shift to generics, market saturation |
Impact of Formulation Changes and Generic Competition
Switching patients to generics can cut revenues by 60-80%. Strategic brand positioning and formulation innovation can mitigate revenue loss. Licensing and regional expansion remain critical.
Regulatory and Policy Considerations
- Regulatory approval processes may delay launches or restrict indications.
- Variations in contraceptive approval status, including over-the-counter availability, influence market access.
- Increasing regulatory scrutiny on safety profiles can impact sales trajectories.
Key Takeaways
- ORTHO-NOVUM 1/35-28 operates within a mature market characterized by steady growth, primarily driven by North American and European markets.
- Patent expirations and rising generic competition will challenge revenue growth, likely leading to a plateau or decline in 2024-2028.
- The product faces challenges from alternative contraceptive methods and changing consumer preferences.
- Regions like Asia-Pacific present growth opportunities due to demographic trends.
- The product's financial trajectory depends on regulatory environment, patent strategies, and effectiveness in maintaining market share through innovation and marketing.
Frequently Asked Questions
How does patent expiry affect ORTHO-NOVUM 1/35-28 revenues?
Patent expiry lowers barriers for generic manufacturers to enter markets, significantly reducing sales prices and market share for the original formulation.
What regions offer the highest growth potential?
Asia-Pacific and Latin America. Demographic trends and increasing contraceptive accessibility underpin growth potential in these regions.
Are there regulatory risks for future sales?
Yes. Changes in approvals, restrictions, or safety guidelines could delay new launches or restrict sales in certain regions.
Can formulation innovations extend the product lifecycle?
Potentially. Reformulations or combination therapies can provide new indications or improved safety profiles to extend market relevance.
How significant is generic competition in the US and Europe?
Very significant. Generics account for over 80% of oral contraceptive prescriptions, severely impacting original brand revenues.
References
[1] Grand View Research. (2022). Contraceptive market size, trend, and forecast.
[2] IQVIA. (2021). Global prescription drug sales report.
[3] U.S. Patent and Trademark Office. (2022). Patent status for contraceptive formulations.
[4] MarketWatch. (2022). Oral contraceptives revenue analysis and competition overview.
[5] World Health Organization. (2022). Family planning and reproductive health statistics.
